278 related articles for article (PubMed ID: 26941846)
1. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.
Liu R; Shi P; Nie Z; Liang H; Zhou Z; Chen W; Chen H; Dong C; Yang R; Liu S; Chen C
Theranostics; 2016; 6(4):533-44. PubMed ID: 26941846
[TBL] [Abstract][Full Text] [Related]
2. Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis.
Liu R; Chen H; Zhao P; Chen CH; Liang H; Yang C; Zhou Z; Zhi X; Liu S; Chen C
Int J Biol Sci; 2020; 16(4):611-619. PubMed ID: 32025209
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.
Lin Y; Liu R; Zhao P; Ye J; Zheng Z; Huang J; Zhang Y; Gao Y; Chen H; Liu S; Zhou J; Chen C; Chen H
Eur J Med Chem; 2018 Feb; 146():354-367. PubMed ID: 29407962
[TBL] [Abstract][Full Text] [Related]
4. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
[TBL] [Abstract][Full Text] [Related]
5. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
Liu R; Zhi X; Zhou Z; Zhang H; Yang R; Zou T; Chen C
Sci Rep; 2018 Jan; 8(1):1138. PubMed ID: 29348684
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
8. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
10. The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27Kip1.
Wang C; Nie Z; Zhou Z; Zhang H; Liu R; Wu J; Qin J; Ma Y; Chen L; Li S; Chen W; Li F; Shi P; Wu Y; Shen J; Chen C
Oncotarget; 2015 Jul; 6(19):17685-97. PubMed ID: 25970772
[TBL] [Abstract][Full Text] [Related]
11. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
12. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
13. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.
Sun X; Li Y; Zheng M; Zuo W; Zheng W
PLoS One; 2016; 11(9):e0162754. PubMed ID: 27618431
[TBL] [Abstract][Full Text] [Related]
15. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.
Shen S; Du XJ; Liu J; Sun R; Zhu YH; Wang J
J Control Release; 2015 Jun; 208():14-24. PubMed ID: 25575864
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer.
Zou H; Luo J; Guo Y; Tong T; Liu Y; Chen Y; Xiao Y; Ye L; Zhu C; Deng L; Wang B; Pan Y; Li P
Cell Mol Life Sci; 2023 Jan; 80(2):41. PubMed ID: 36633714
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.
Shen Y; Zhu Q; Xiao M; Yin L; Feng W; Feng J; He J; Li P; Chen X; Ding W; Zhong J; Zeng Z; Xie Z; Liu J; Zu X
Cell Death Dis; 2022 Aug; 13(8):749. PubMed ID: 36042208
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
19. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation.
Shi P; Liu W; Tala ; Wang H; Li F; Zhang H; Wu Y; Kong Y; Zhou Z; Wang C; Chen W; Liu R; Chen C
Cell Discov; 2017; 3():17010. PubMed ID: 28480051
[TBL] [Abstract][Full Text] [Related]
20. YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway.
Chen Z; Wu Q; Ding Y; Zhou W; Liu R; Chen H; Zhou J; Feng J; Chen C
Theranostics; 2017; 7(8):2339-2349. PubMed ID: 28740556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
